502 related articles for article (PubMed ID: 33921360)
41. Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?
Menzella F; Latorre M; Ruggiero P; Bagnasco D; Heffler E
Expert Opin Biol Ther; 2019 Jul; 19(7):601-606. PubMed ID: 31033373
[No Abstract] [Full Text] [Related]
42. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
43. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.
Jackson DJ; Korn S; Mathur SK; Barker P; Meka VG; Martin UJ; Zangrilli JG
Drug Saf; 2020 May; 43(5):409-425. PubMed ID: 32242310
[TBL] [Abstract][Full Text] [Related]
44. Exacerbations of Severe Asthma While on Anti-IL-5 Biologics.
Bhalla A; Zhao N; Rivas DD; Ho T; Perez de Llano L; Mukherjee M; Nair P
J Investig Allergol Clin Immunol; 2020; 30(5):307-316. PubMed ID: 32573459
[TBL] [Abstract][Full Text] [Related]
45. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
[No Abstract] [Full Text] [Related]
46. Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies.
Pavord ID; Hanania NA
J Allergy Clin Immunol Pract; 2019; 7(5):1430-1436. PubMed ID: 30962155
[No Abstract] [Full Text] [Related]
47. Mepolizumab: A Review in Eosinophilic Asthma.
Deeks ED
BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
[TBL] [Abstract][Full Text] [Related]
48. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.
Cazzola M; Matera MG; Levi-Schaffer F; Rogliani P
Expert Opin Drug Saf; 2018 Apr; 17(4):429-435. PubMed ID: 29486600
[TBL] [Abstract][Full Text] [Related]
49. Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study.
Vantaggiato L; Perruzza M; Refini RM; Bergantini L; d'Alessandro M; Cameli P; Perruzza D; Bini L; Bargagli E; Landi C
Lung; 2020 Oct; 198(5):761-765. PubMed ID: 32691140
[TBL] [Abstract][Full Text] [Related]
50. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
[TBL] [Abstract][Full Text] [Related]
51. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma.
Menzella F; Ruggiero P; Galeone C; Scelfo C; Bagnasco D; Facciolongo N
Pulm Pharmacol Ther; 2020 Oct; 64():101966. PubMed ID: 33039666
[TBL] [Abstract][Full Text] [Related]
52. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
53. Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma.
Kupczyk M; Kuna P
Immunotherapy; 2018 Apr; 10(5):349-359. PubMed ID: 29359607
[TBL] [Abstract][Full Text] [Related]
54. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.
Molfino NA; Gossage D; Kolbeck R; Parker JM; Geba GP
Clin Exp Allergy; 2012 May; 42(5):712-37. PubMed ID: 22092535
[TBL] [Abstract][Full Text] [Related]
55. Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma.
Matucci A; Maggi E; Vultaggio A
Respir Med; 2019; 160():105819. PubMed ID: 31734469
[TBL] [Abstract][Full Text] [Related]
56. Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.
Domingo C
Drugs; 2017 Oct; 77(16):1769-1787. PubMed ID: 28948572
[TBL] [Abstract][Full Text] [Related]
57. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):1-8. PubMed ID: 31136278
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
Corren J
Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
[TBL] [Abstract][Full Text] [Related]
59. Role of eosinophilic chronic rhinosinusitis in switching to benralizumab treatment in mepolizumab responders.
Hamada S; Kobayashi Y; Yasuba H
Int J Clin Pharmacol Ther; 2020 Dec; 58(12):703-708. PubMed ID: 32831163
[TBL] [Abstract][Full Text] [Related]
60. Benralizumab as a potential treatment of asthma.
Antoniu SA
Expert Opin Biol Ther; 2017 Jul; 17(7):895-900. PubMed ID: 28406319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
